Artan Markollari, MD
Family Medicine · Hazelwood, MONPI 1174726046
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $970, 9.6 times the $101 reported in 2019.
Across 214 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$528
- Novo Nordisk$524
- Lilly USA, LLC$501
- AbbVie$347
- Pfizer$292
- AstraZeneca$213
- plus $1K from 21 others
Across 40 payments — averaging $10,681 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Banner Life Sciences, LLC$323K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$83K
- Chiasma, Inc.$12K
- Amryt Pharma Holdings Ltd$10K
What the payments were for
- Food & beverage$3,595100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 34 | $528 |
| Novo Nordisk | 31 | $524 |
| Lilly USA, LLC | 26 | $501 |
| AbbVie | 19 | $347 |
| Pfizer | 24 | $292 |
| AstraZeneca | 13 | $213 |
| Sanofi-aventis U.S. LLC | 9 | $163 |
| Amgen | 8 | $157 |
| Johnson & Johnson | 7 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $110 |
| Boehringer Ingelheim | 7 | $99 |
| Abbott | 5 | $98 |
| Ironwood Pharmaceuticals, Inc | 3 | $61 |
| Bayer | 3 | $59 |
| Novartis | 3 | $56 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $55 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Exact Sciences | 2 | $28 |
| Edwards Lifesciences | 1 | $22 |
| Lundbeck LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Cranial Technologies, Inc | 1 | $14 |
| Merck | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$3,595 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 149 | $208,995 |
| JardianceEmpagliflozin | 122 | $139,214 |
| TrulicityDulaglutide | 61 | $131,901 |
| MounjaroTirzepatide | 87 | $117,678 |
| FarxigaDapagliflozin Propanediol | 69 | $69,681 |
| RybelsusSemaglutide | 49 | $65,961 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $58,186 |
| EliquisApixaban | 42 | $38,543 |
| LinzessLinaclotide | 47 | $30,969 |
| JanuviaSitagliptin Phosphate | 23 | $30,010 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $27,701 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $26,562 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $25,449 |
| XareltoRivaroxaban | 34 | $23,000 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $22,342 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30 | $524 | $278,587209 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $501 | $249,579148 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $99 | $159,251148 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $213 | $114,087122 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $528 | $70,007116 claims |
| MerckJanuvia, Janumet Xr, Dulera, Steglatro | $13 | $62,85671 claims |
| PfizerEliquis | $292 | $38,54342 claims |
| AbbVieLinzess | $347 | $30,96947 claims |
| Johnson & JohnsonXarelto | $127 | $23,00034 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $163 | $15,69912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Hazelwood
- Stephen AdamsSpringfield$636K
- Justin PuckettKirksville$568K
- Matthew BeckerditeOfallon$225K
- Roger CadySpringfield$175K
- James LasalleExcelsior Springs$130K
- Matthew TiefenbrunnSullivan$105K
- Ayobami OduwoleGrandview$92K
- Michael DonovanSaint Louis$78K
- Blair ThedingerKansas City$71K
- Christine MooreRaymore$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.